Frontiers in neurology · 2025
Humanistic burden and medical care patterns of real-world patients with myasthenia gravis in Japan.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kasahara-Kiritani Mami, Saga Yosuke, Watanabe Sayuri, Webb Thomas, Herr Keira, Yu DaeYoung, Ringland Ciara, Birija Shiva Lauretta, Conyers Joe, Gibson Gregor, Hatchell Niall, Li Nan
Аннотация
INTRODUCTION: Myasthenia gravis (MG) is a rare autoimmune disease characterized by skeletal muscle weakness. As limited real-world data are available in Japan, we aimed to describe the humanistic burden of disease (primary aim), mainly with regards to health-related quality of life (HRQoL), and treatment patterns (secondary aim) in patients with generalized MG (gMG).
METHODS: Data were drawn from the Adelphi Real World MG Disease Specific Programme™, a cross-sectional survey of neurologists and their patients in Japan from August 2023 and January 2024. Analyses were descriptive.
RESULTS: Overall, 40 neurologists reported data for 128 patients, where 29 patients had self-reported data. Mean (standard deviation) patient age was 57.9 (16.0) years and 53.9% were female. At data collection, 98.4% of patients were receiving maintenance therapy (including novel treatments). Nonsteroidal immunosuppressant therapies were used at first-line of therapy in 54.5% of cases (n = 67/123). Oral systemic steroids were most used [78.0% of patients at first-line (n = 96/123), 77.9% at second-line (n = 53/68), and 75.0% at third-line (n = 15/20)]. The median (IQR) duration from symptom onset to diagnosis was 2.0 (0.9-4.3) months. Of 28 patients with EQ-5D-5L data, 46.4% reported difficulties with usual activities, 42.9% with mobility, 21.4% with self-care, 53.6% with pain/discomfort, and 39.3% with anxiety/depression.
CONCLUSION: Most patients in this Japanese cohort with gMG received maintenance therapy and the time from symptom onset to diagnosis was relatively short. However, impaired HRQoL remained.
METHODS: Data were drawn from the Adelphi Real World MG Disease Specific Programme™, a cross-sectional survey of neurologists and their patients in Japan from August 2023 and January 2024. Analyses were descriptive.
RESULTS: Overall, 40 neurologists reported data for 128 patients, where 29 patients had self-reported data. Mean (standard deviation) patient age was 57.9 (16.0) years and 53.9% were female. At data collection, 98.4% of patients were receiving maintenance therapy (including novel treatments). Nonsteroidal immunosuppressant therapies were used at first-line of therapy in 54.5% of cases (n = 67/123). Oral systemic steroids were most used [78.0% of patients at first-line (n = 96/123), 77.9% at second-line (n = 53/68), and 75.0% at third-line (n = 15/20)]. The median (IQR) duration from symptom onset to diagnosis was 2.0 (0.9-4.3) months. Of 28 patients with EQ-5D-5L data, 46.4% reported difficulties with usual activities, 42.9% with mobility, 21.4% with self-care, 53.6% with pain/discomfort, and 39.3% with anxiety/depression.
CONCLUSION: Most patients in this Japanese cohort with gMG received maintenance therapy and the time from symptom onset to diagnosis was relatively short. However, impaired HRQoL remained.